Researchers at the German Cancer Research Center (DKFZ) in Heidelberg have unveiled a game-changing artificial intelligence system that diagnoses over 100 molecular subtypes of brain tumors with 95% accuracy in approximately five minutes. Published in Nature Cancer, this breakthrough leverages standard hematoxylin and eosin (H&E) tissue staining—a technique available in pathology labs worldwide for more than a century—eliminating the need for expensive molecular testing infrastructure.
The study, which analyzed 2,334 tumor samples across multiple centers, demonstrates that the AI system can deliver comprehensive tumor classification during surgery itself, enabling real-time surgical decision-making. This innovation has significant implications for global healthcare equity, particularly in resource-limited regions where molecular diagnostic capabilities remain inaccessible. By reducing diagnosis time from 2-6 weeks to just minutes while maintaining exceptional accuracy, this technology could democratize precision brain tumor diagnosis worldwide and fundamentally reshape how oncologists approach CNS tumor management.
Read the full article on GMJ Newsroom.
Was this article helpful?
